Based on recent evidence that Mfn2 exists in both active and inactive states, pharmacologically unfolding endogenous mitofusins to promote mitochondrial tethering and fusion could prove beneficial in treating CMT2A. This evidence concerns the gene MFN2 and Charcot-Marie-Tooth disease type 2A1.